Epaldeudomide

Tier C — Watch / trade

Epaldeudomide

Originator

First approval

Expiry (public)

No sales data

Peak sales

Type

Targets：CRBN, IKZF3, IKZF1

Indications (approved)：Systemic lupus erythematosus, Adult T-cell leukaemia/lymphoma, Multiple myeloma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Mantle cell lymphoma, Haematological malignancy

Regional status

Phase II

2021-06-03

China

Phase I

2024-04-13

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Epaldeudomide?

Approved indications include: Systemic lupus erythematosus, Adult T-cell leukaemia/lymphoma, Multiple myeloma, Follicular lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Mantle cell lymphoma, Haematological malignancy.

When does the Epaldeudomide patent expire?

No public expiry year is available for Epaldeudomide yet; this page updates once verified.

How do I get a quote for Epaldeudomide intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21